Veeva Systems has launched Veeva AI, a major new initiative bringing generative AI to its cloud platform and applications.

The tools aim to help life sciences companies boost productivity, automate workflows and speed up development timelines.

The system, revealed today, will be rolled out across all Veeva Vault applications—including those used for clinical trials, regulatory submissions, pharmacovigilance, quality management, medical affairs, and commercial functions. It will support both Veeva-delivered and customer-configured AI Agents, as well as personalized AI Shortcuts, allowing organizations to automate repetitive tasks and generate contextual insights based on their specific needs.

“Core applications give you structured data, business rules and workflow,” said Peter Gassner, CEO of Veeva.

“GenAI brings the more human-like ability to derive answers and insights from ambiguous situations that deal with language, context, and broad-based knowledge. Core applications and GenAI working seamlessly together will bring significant productivity gains.”

At the heart of the initiative are two new capabilities: AI Agents and AI Shortcuts. AI Agents are intelligent assistants tailored to specific Veeva applications, preloaded with application-aware prompts and secure access to customer data and workflows. These can be deployed quickly to carry out predefined tasks, with the flexibility to build custom agents or access them via API. End users, meanwhile, will be able to create AI Shortcuts—simple, personalized automations to speed up tasks like workflow assistance, data queries, and contextual research.

Importantly, Veeva AI is LLM-agnostic, meaning customers can either use Veeva’s pre-integrated language models or connect their own, offering flexibility while maintaining strict data security. The company says customer data will remain securely partitioned, no matter the AI model deployed.

The initiative marks a notable shift in how life sciences organizations can integrate generative AI without the typical risk and complexity. According to Veeva, this level of integration allows companies to scale AI use cases across critical business processes—supporting goals like faster drug development, improved compliance, and operational efficiency.

The first release of Veeva AI is expected in December 2025, and it will be licensed at the Vault level with what the company describes as a “simple and reasonable subscription fee” to support widespread adoption across the sector.